Prognostic values of immune efficacy biomarkers in the treatment of nasopharyngeal carcinoma / 国际肿瘤学杂志
Journal of International Oncology
; (12): 743-746, 2021.
Article
in Zh
| WPRIM
| ID: wpr-930032
Responsible library:
WPRO
ABSTRACT
Immunotherapy has achieved objective response rates of 20%-30% in patients with recurrent or metastatic nasopharyngeal carcinoma, but fewer people are benefiting. Studies have shown that patients with nasopharyngeal carcinoma carrying high expression of programmed death-1/programmed death-ligand 1 and/or high tumor mutation burden have a significant response to immunotherapy. Biomarkers of the tumor microenvironment, especially tumor infiltrating lymphocyte, are abundant in nasopharyngeal carcinoma, varying from different Epstein-Barr virus states, which can also play a predictive role of immunotherapy efficacy. Other biomarkers, such as mismatch repair-deficient, have a low incidence in nasopharyngeal carcinoma and limited predictive power. Combined detection of different types of immunotherapeutic biomarkers is more helpful to identify suitable populations for immunotherapy.
Full text:
1
Index:
WPRIM
Type of study:
Prognostic_studies
Language:
Zh
Journal:
Journal of International Oncology
Year:
2021
Type:
Article